X

Drug Profile

Research programme: YBX1 antagonists - Genesis Research and Development Corporation/Amgen

Latest Information Update: 14 Mar 2008

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amgen; Genesis Research and Development
Class
Mechanism of Action YBX1 protein antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer

Most Recent Events

14 Mar 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
02 Aug 2002 This programme is still in active development
29 Jul 2002 Immunex was acquired by, and merged into, Amgen.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com